{
  "id": "5c663e277c78d69471000015",
  "type": "summary",
  "question": "What is the mechanism of action of motolimod?",
  "ideal_answer": "Motolimod is the toll-like receptor 8 (TLR8) agonist that stimulates innate and adaptive immunity.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29345064",
    "http://www.ncbi.nlm.nih.gov/pubmed/27702821",
    "http://www.ncbi.nlm.nih.gov/pubmed/29931076",
    "http://www.ncbi.nlm.nih.gov/pubmed/28453702",
    "http://www.ncbi.nlm.nih.gov/pubmed/26928328",
    "http://www.ncbi.nlm.nih.gov/pubmed/27467937",
    "http://www.ncbi.nlm.nih.gov/pubmed/28485332",
    "http://www.ncbi.nlm.nih.gov/pubmed/27810904",
    "http://www.ncbi.nlm.nih.gov/pubmed/26152744"
  ],
  "snippets": [
    {
      "text": "We investigated expression of TLR8 on MDSC and the effect of a TLR8 agonist, motolimod, on MDSC survival and function.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29345064",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The toll-like receptor 8 (TLR8) agonist motolimod may stimulate innate and adaptive immunity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29931076",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We sought to develop a rational combination of motolimod-a novel Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses in humans but diminished responses in mice-with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27702821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27810904",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Motolimod (VTX-2337), a selective small-molecule agonist of TLR8, stimulates natural killer (NK) cells, dendritic cells, and monocytes. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27810904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background: A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of motolimod-a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses-combined with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453702",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Motolimod effectively drives immune activation in advanced cancer patients.A novel approach to immunotherapy is the activation of toll-like receptor 8 (TLR8). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27467937",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152744",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We sought to develop a rational combination of motolimod-a novel Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses in humans but diminished responses in mice-with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death.Experimental Design: We followed an integrative pharmacologic approach including healthy human volunteers, non-human primates, NSG-HIS (\"humanized immune system\") mice reconstituted with human CD34+ cells, and patients with cancer to test the effects of motolimod and to assess the combination of motolimod with PLD for the treatment of ovarian cancer.Results: The pharmacodynamic effects of motolimod monotherapy in NSG-HIS mice closely mimicked those in non-human primates and healthy human subjects, whereas the effects of the motolimod/PLD combination in tumor-bearing NSG-HIS mice closely mimicked those in patients with ovarian cancer treated in a phase Ib trial (NCT01294293).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27702821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Motolimod (VTX-2337), a selective small-molecule agonist of TLR8, stimulates natural killer (NK) cells, dendritic cells, and monocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27810904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The activity of motolimod (VTX-2337), a potent and selective Toll-like receptor 8 (TLR8) agonist, was therefore assessed in the context of advanced, late-stage cancer patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152744",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nLate-stage cancer patients are highly sensitive to TLR8 activation by motolimod.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152744",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Translational studies in cynomolgus monkeys elucidated the activity of motolimod on an intact immune system, identified biomarkers of TLR8 activation, and defined the relationship between the pharmacokinetic and pharmacodynamic (PK/PD) response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152744",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "UNLABELLED\nVTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an immunotherapy for multiple oncology indications, including squamous cell carcinoma of the head and neck (SCCHN).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26928328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Motolimod, a selective TLR8 agonist can act in concert with approved immunotherapies to sensitize T cells and augment natural killer (NK) cell function.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27467937",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "UNLABELLED VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an immunotherapy for multiple oncology indications, including squamous cell carcinoma of the head and neck (SCCHN).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26928328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Immunotherapy represents an attractive treatment option for R/M HNSCC, with encouraging preliminary data from studies involving immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) and toll-like receptor agonists (e.g., motolimod).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28485332",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The toll-like receptor 8 (TLR8) agonist motolimod may stimulate innate and adaptive immunity.<br><b>Objective</b>: To determine whether motolimod improves outcomes for R/M SCCHN when combined with standard therapy.<br><b>Design, Setting, and Participants</b>: The Active8 study was a multicenter, randomized, double-blind, placebo-controlled clinical trial enrolling adult patients (age \u226518 years) with histologically confirmed R/M SCCHN of the oral cavity, oropharynx, hypopharynx, or larynx between October 2013 and August 2015.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29931076",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition, the PK/PD response in cancer patients closely aligned with the activity of motolimod seen in healthy volunteers.<br><b>CONCLUSIONS</b>: Late-stage cancer patients are highly sensitive to TLR8 activation by motolimod.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152744",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Late-stage cancer patients are highly sensitive to TLR8 activation by motolimod.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152744",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We sought to develop a rational combination of motolimod-a novel Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses in humans but diminished responses in mice-with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death.Experimental Design: We followed an integrative pharmacologic approach including healthy human volunteers, non-human primates, NSG-HIS (humanized immune system) mice reconstituted with human CD34+ cells, and patients with cancer to test the effects of motolimod and to assess the combination of motolimod with PLD for the treatment of ovarian cancer.Results: The pharmacodynamic effects of motolimod monotherapy in NSG-HIS mice closely mimicked those in non-human primates and healthy human subjects, whereas the effects of the motolimod/PLD combination in tumor-bearing NSG-HIS mice closely mimicked those in patients with ovarian cancer treated in a phase Ib trial (NCT01294293).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27702821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The activity of motolimod (VTX-2337), a potent and selective Toll-like receptor 8 (TLR8) agonist, was therefore assessed in the context of advanced, late-stage cancer patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152744",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of motolimod-a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses-combined with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453702",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}